GlassScriptPhysician profile
David P Magier
NPI 1285634196
$24,442.22
in general payments reported to CMS, 2019-2025
36 companies · $3,735 in 2025
The $3,735 reported for 2025 was more than what 97% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $6,554 · 2020: $2,486 · 2021: $2,458 · 2022: $3,765 · 2023: $2,322 · 2024: $3,122 · 2025: $3,735.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,178.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,178.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $5,505.83 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $2,706.19 | 2019-2025 | Xifaxan, Trulance |
| Gilead Sciences, INC. | $2,456.96 | 2019-2025 | Vemlidy, Livdelzi |
| Madrigal Pharmaceuticals | $2,009.78 | 2024-2025 | Rezdiffra, Resmetirom |
| E.R. Squibb & Sons, L.L.C. | $1,902.82 | 2021-2024 | Zeposia |
| Amgen INC. | $1,084.93 | 2019-2023 | Repatha |
| Ardelyx, INC. | $1,060.16 | 2022-2025 | Ibsrela |
| Phathom Pharmaceuticals, INC. | $848.30 | 2024-2025 | Voquezna |
| Pfizer INC. | $772.96 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $758.29 | 2019-2022 | |
| Nestle Healthcare Nutrition INC. | $718.32 | 2020-2022 | |
| Celgene Corporation | $651.74 | 2022-2024 | Zeposia |
| Abbvie INC. | $495.63 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $488.36 | 2020-2023 | Breztri |
| Teva Pharmaceuticals USA, INC. | $375.01 | 2022 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ipsen Biopharmaceuticals, INC | $319.22 | 2025 | Iqirvo |
| Novo Nordisk INC | $316.06 | 2019-2025 | Wegovy |
| Redhill Biopharma INC. | $305.76 | 2021-2022 | |
| Ferring Pharmaceuticals INC. | $207.43 | 2019-2020 | |
| Kowa Pharmaceuticals America, INC. | $178.41 | 2019-2022 | |
| Regeneron Healthcare Solutions, INC. | $167.71 | 2022-2025 | Dupixent |
| Janssen Biotech, INC. | $155.97 | 2025 | Tremfya |
| Astellas Pharma US INC | $151.50 | 2019-2022 | |
| Genzyme Corporation | $142.14 | 2023 | |
| Intercept Pharmaceuticals, INC. | $125.00 | 2022 | |
| Evoke Pharma, INC. | $118.40 | 2023 | Gimoti |
| Merck Sharp & Dohme LLC | $109.40 | 2019 | |
| Amarin Pharma, INC. | $80.73 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $77.86 | 2020-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $52.01 | 2019-2021 | |
| Braintree Laboratories, INC. | $38.30 | 2019 | |
| Lilly USA, LLC | $15.55 | 2022 | |
| Arbor Pharmaceuticals, INC. | $15.04 | 2021 | |
| Boston Scientific Corporation | $12.55 | 2019 | |
| Seqirus USA INC | $11.14 | 2019 | |
| Qol Medical, LLC | $6.76 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Magier listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.